Call for Independent Medical Education Grant Applications Oncology – Urothelial Carcinoma (UC)

Call for Independent Medical Education Grant Applications Oncology – Urothelial Carcinoma (UC)

Astellas and Pfizer Inc. (collectively, the Companies) are committed to supporting high-quality, evidence-based independent medical education (IME) that seeks to improve the overall safety and quality of patient care and treatment. The intent of this Call for Grant Applications (CGA) is to seek applications for independent Continuing Medical Education / Continuing Education (CME/CE) designed to close knowledge gaps identified in the public healthcare landscape, drive measurable improvements in knowledge, competence, and performance of healthcare professionals, and advance patient health outcomes. “Independent” means that the projects funded are the full responsibility of the recipient organization. The Companies shall have no influence over any aspect of the supported projects and only ask for status updates, and quarterly interim and final outcomes reports including a description of the overall impact of the project.

Eligibility

_You can learn more about this opportunity by visiting the funder's website._

• Geographic Scope:
  • Global - priority target audience is outside of the United States. At a minimum, proposals must have multi-country/regional reach.
• Applicant Eligibility Criteria:
  • Eligible applicants include Global Medical Education Providers with experience in executing IME with the capability of multiple language translations and global distribution channels.
  • Collaborations between organizations and within institutions are acceptable.
  • Please note all partners must have a relevant role and the requesting Organization must lead the project.
  • For all US-based organizations only, the accrediting organization must be the primary requestor on the grant application.
• Specific Education Gaps To Be Addressed:
  • The purpose of this CGA is to encourage Organizations with ex - US experience to submit grant applications for independent either accredited or non-accredited activities designed to enhance understanding of the management of urothelial carcinoma (UC).
  • Knowledge gaps in Urothelial Carcinoma which have been identified in the public healthcare landscape include:
  • Evolving therapeutic options for patients with locally advanced (la) or metastatic urothelial carcinoma (mUC)
  • Emerging treatment options in the 1L setting and the holistic management of patients with UC, including combination regimens and optimal sequencing
  • Recent updates to treatment guidelines
  • Adverse event management in current and emerging treatment options in la/mUC
  • Early identification and management of adverse events associated with UC treatment within the multidisciplinary team
  • Importance of patient education
  • The future treatment landscape in Muscle Invasive Bladder Cancer (MIBC) setting
  • Perioperative approach in the MIBC setting
  • The role of a multi-disciplinary team in MIBC management
  • Impact of systemic therapy in MIBC on la/mUC treatment choice
  • Proposals must address at least two of the three knowledge gaps identified above.
  • Proposals that address multiple gaps from the above list, and activities with a global reach and innovative dissemination and engagement approaches, will be prioritized.
  • The primary language of the program must be English.
  • Language translation must be included in any proposed enduring components in one of the following:
  • Portuguese, Japanese, German, Spanish, and/or French.